Browsing Tag
Keytruda
52 posts
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA
Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA.
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
Merck’s KEYTRUDA + WELIREG combo shows major disease-free survival benefit in clear cell renal cell carcinoma after surgery
Find out how Merck’s KEYTRUDA + WELIREG combo improved disease-free survival after kidney cancer surgery and what it means for the oncology market.
Bladder cancer breakthrough: FDA gives Priority Review to Merck’s KEYTRUDA and KEYTRUDA QLEX + PADCEV combinations
Find out how Merck’s KEYTRUDA and new KEYTRUDA QLEX + PADCEV combinations are set to transform treatment for muscle-invasive bladder cancer — read more now
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.